Article

Clinical Implication of Monitoring Circulating Tumor DNA in Untreated Non-Small-Cell Lung Cancer Patients

2021-06-28

Abstract excerpt

CtDNA has been utilized to monitor the clinical course of the patients of NSCLC who receive therapies targeting druggable mutations. However, despite providing valuable information on how NSCLC would naturally progress, the clinical utility of ctDNA for clinical-course monitoring and prediction of the treatment-naïve NSCLC patients without druggable mutations remain unknown. We longitudinally followed a total of 1...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b6ec8ad2-c556-5d8a-adc0-17fdbb321fea
DOI: 10.21203/rs.3.rs-640389/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Clinical Implication of Monitoring Circulating Tumor DNA in Untreated Non-Small-Cell Lung Cancer PatientsDOI 10.21203/rs.3.rs-640389/v1Read

Monitoring Circulating Tumor DNA in Untreated Non-Small-Cell Lung Cancer Patients.Semantic proximity Read

Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response.Semantic proximity Read

Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction.Semantic proximity Read

The Utility of ctDNA in Lung Cancer Clinical Research and Practice: A Systematic Review and Meta-Analysis of Clinical Studies.Semantic proximity Read

Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.Semantic proximity Read

The promises and perils of circulating tumor DNA for monitoring immunotherapy response in non-small cell lung cancerSemantic proximity Read

Role of circulating-tumor DNA analysis in non-small cell lung cancer.Semantic proximity Read

Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA.Semantic proximity Read

Correlation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR-mutated non-small cell lung cancer.Semantic proximity Read

Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer.Semantic proximity Read

Clinical Utility of ctDNA Analysis in Lung Cancer—A ReviewSemantic proximity Read

Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation.Semantic proximity Read